Browsing Tag
ciltacabtagene autoleucel
3 posts
Legend Biotech (NASDAQ: LEGN) CARVYKTI scaling meets LB2102 solid tumor signal
Legend Biotech (NASDAQ: LEGN) printed 62% CARVYKTI growth and a solid tumor CAR-T signal. The 2026 profitability target is the next real test.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…